Stockreport

Cell & Gene Therapies in CNS Disorders Report 2025 - Zolgensma & Elevidys Lead Booming Cell & Gene Therapies in CNS Disorders [Yahoo! Finance]

Sarepta Therapeutics, Inc.  (SRPT) 
Last sarepta therapeutics, inc. earnings: 2/26 04:05 pm Check Earnings Report
PDF CGTs including Novartis's Zolgensma and Sarepta's Elevidys, targeting disorders like SMA, DMD, MLD, and CALD. It features market insights, pipeline analysis, regulatory [Read more]